Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
212M
-
Number of holders
-
110
-
Total 13F shares, excl. options
-
51.2M
-
Shares change
-
-1.34M
-
Total reported value, excl. options
-
$27.7M
-
Value change
-
-$1.37M
-
Put/Call ratio
-
0.71
-
Number of buys
-
44
-
Number of sells
-
-55
-
Price
-
$0.54
Significant Holders of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) as of Q2 2025
145 filings reported holding SGMO - SANGAMO THERAPEUTICS, INC - Common Stock as of Q2 2025.
SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) has 110 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 51.2M shares
of 212M outstanding shares and own 24.16% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (9.37M shares), WASATCH ADVISORS LP (8.08M shares), RENAISSANCE TECHNOLOGIES LLC (6.84M shares), BlackRock, Inc. (4.81M shares), GEODE CAPITAL MANAGEMENT, LLC (2.33M shares), GSA CAPITAL PARTNERS LLP (2.25M shares), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (1.28M shares), Ikarian Capital, LLC (1.26M shares), UBS Group AG (1.25M shares), and TWO SIGMA ADVISERS, LP (1.21M shares).
This table shows the top 110 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.